Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
CAR T-cell therapy is a groundbreaking form of immunotherapy revolutionizing cancer treatment, and its recent advancements have been remarkable. However, as the therapy expands across new indications and into earlier lines of therapy, challenges emerge. Finding its place in a well-established standard of care may pose significant hurdles, especially when alternative treatments such as new targeted therapies arise.
During this webinar, IQVIA’s Carolina Ricarte, Offering Development Director and Vladimir Bonevski, Associated Product & Strategy Director will provide unique insights from IQVIA’s market research studies, CAR T-cell Monitor & Oncology retrospective chart reviews, around:
In this session, you will also hear directly from CAR T-cell pioneer, Professor Jérôme Larghero, Director of the MEARY Center, France, recognized for the substantial contributions to CAR T-cell therapy research and applications such as:
Jérôme Larghero Director, MEARY Center, France |
|
Carolina Ricarte Offering Development Director, IQVIA |
|
Vladimir Bonevski Associate Director, Global Oncology Product & Strategy, IQVIA |
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.